Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (583)	11/16/2006 4:25:08 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

The early news didn't help the stock price until the afternoon when AP & BizJournal started to repeat it.<g> Introgen Acquires Rights to New Nanotechnology Systems Thursday November 16, 7:00 am ET Targeted Nanoparticles Used to Deliver Proteins, Polypeptides and Peptides AUSTIN, Texas, Nov. 16 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - News) announced today that it has obtained the exclusive, worldwide license to a portfolio of patents from The University of Texas M. D. Anderson Cancer Center focused on the delivery of biologically active proteins, polypeptides and peptides using novel nanoparticle delivery complexes. The technology has demonstrated substantial therapeutic efficacy against human lung cancers in animal models. The systemically-delivered nanoparticles are applicable to a wide variety of bioactive protein-derived molecules. The licensed technology is directed to specially designed nanoparticles that carry and deliver therapeutic bioactive proteins, polypeptides and peptides to targeted cells, such as cancer cells. These nanoparticle formulations have certain therapeutic advantages. While peptides alone may be rapidly removed from circulation, requiring frequent administration and high doses, Introgen's nanoparticle-polypeptide formulations can increase therapeutic activity and protect against rapid degradation normally associated with peptide therapy. In addition, Introgen's peptide nanoparticles can include special targeting molecules to further enhance cellular uptake and to improve therapeutic efficacy. "Acquiring rights to these nanoparticle delivery technologies represents a significant addition to Introgen's drug delivery platforms," said David G. Nance, Introgen's Chief Executive Officer. "While our existing programs include nanoparticle delivery of tumor suppressor genes, the new technology expands our capabilities to include delivery of therapeutic peptides and polypeptides as well as proteins. We expect these technologies to enable important advances in the targeted delivery of a variety of therapeutic biologics." Introgen currently has three therapeutic nanoparticle product candidates: INGN 401 (nanoparticle FUS-1), INGN 402 (nanoparticle p53) and INGN 403 (nanoparticle mda-7). INGN 401 is currently in phase 1 clinical testing for metastatic lung cancer. Snip But the stock managed to have a late rally.<g> bigcharts.marketwatch.com Bernard